Advertisement

(R)(+)-N-Propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B

  • J. Sterling
  • A. Veinberg
  • D. Lerner
  • W. Goldenberg
  • R. Levy
  • M. Youdim
  • J. Finberg
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)

Summary

(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase inhibitory activity. Rasagiline and several analogues were found be highly selective and potent inhibitors of the B form of the enzyme in contrast to the levorotatory enantiomer which was not active. The results indicate that rasagiline has potential for the treatment of Parkinson’s Disease. This compound is currently under development for that indication.

Keywords

Monoamine Oxidase Irreversible Inhibitor Parkinson Study Group Absolute Stereochemistry 1Teva Pharmaceutical Industry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) Potentiation of antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, l-deprenyl. J Neural Transm 36: 303–323PubMedCrossRefGoogle Scholar
  2. Engberg G, Elebring T, Nissbrandt H (1991) Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites. J Pharmacol Exp Ther 259: 841–847PubMedGoogle Scholar
  3. Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN-1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73: 65–74PubMedCrossRefGoogle Scholar
  4. Ghislandi V, Vercesi D (1976) Scissione ottica E configurazione dell’1-aminobenzociclobutaene e dell’1-aminoindano. Boll Chim Farm 115: 489–500PubMedGoogle Scholar
  5. Hazelhoff B, De Vries J, Dijkstra D, de Jong W, Horn A (1985) The neuro-pharmacological profile of N-Methyl-N-propargyl-2-aminotetralin. Naunyn Schmiedebergs Arch Pharmacol 330: 50–59PubMedCrossRefGoogle Scholar
  6. Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic “suicide” and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73: 55–64PubMedCrossRefGoogle Scholar
  7. Martin Y, Martin W, Taylor J (1975) Regression analysis of the relationship between physical properties and the in vitro inhibition of monoamine oxidase by propynylamines. J Med Chem 18: 883–888PubMedCrossRefGoogle Scholar
  8. O’Carrol AM, Fowler CJ, Philips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 332: 198–202CrossRefGoogle Scholar
  9. Otsaka S, Kobayashi Y (1964) A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 13: 995–1006CrossRefGoogle Scholar
  10. Parkinson Study Group. DATATOP (1989) A multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46: 1052–1060CrossRefGoogle Scholar
  11. Parkinson Study Group. DATATOP (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183CrossRefGoogle Scholar
  12. Polymeropoulos E (1993) 1-Deprenyl: a unique MAO-B inhibitor. In: Szelenyi I (ed) Inhibitors of monoamine oxidase. Birkhäuser, Basel, pp 109–124Google Scholar
  13. Sterling J, Levy R, Veinberg A, Goldenberg W, Finberg J, Youdim MBH, Gutman A (1996) Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase. USP 4, 486, 541Google Scholar
  14. Youdim MBH (1995) The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand 91[Suppl 386]: 5–7CrossRefGoogle Scholar
  15. Youdim MBH, Finberg J, Levy R, Sterling J, Lerner D, Berger-Peskin T, Yellin H (1995) R-Enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them. USP 5, 457, 133Google Scholar
  16. Yu P, David B, Boulton A (1992) Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 35: 3705–3713PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • J. Sterling
    • 1
    • 1
  • A. Veinberg
    • 1
  • D. Lerner
    • 1
  • W. Goldenberg
    • 1
  • R. Levy
    • 1
  • M. Youdim
    • 2
  • J. Finberg
    • 2
  1. 1.Teva Pharmaceutical IndustriesJerusalemIsrael
  2. 2.Department of PharmacologyRappaport Faculty of Medicine, TechnionHaifaIsrael

Personalised recommendations